If SIGA's drug has substantial worth it stands to reason a larger company would offer to buy both SIGA and PIP for a combined pittance (at these prices). Since no large company appears to be interested and taking the bait it seems the bait ain't worth much. In other words, the hype about a substantial payday and not the product is what has kept both companies' shares afloat.
The intelligent company, owning both SIGA and PIP, would win no matter how the litigation turns out. That is, of course, if SIGA's drug is what it is trumped up to be. It is therefore troubling to see there is no apparent interest in these companies except that inspired by multi-ID'd posters.